News|Articles|September 18, 2009

Semisolid Formulation Development: The CRO Approach - SP Formulations Whitepaper

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Regulatory Roundup—August 2026

BySusan Haigney

August 31st 2026

n-nitrosodimethylamine molecular structure, 3d model molecule, dimethylnitrosamine, structural chemical formula view from a microscope | Image Credit: ©Сергей Шиманович -stock.adobe.com

From Detection to Prediction: Analytical Approaches for Nitrosamine Risk

ByChris Williams

August 31st 2026

Lilly and Samsung Biologics make important moves in Pharma M&A

Lilly's $2.875B Merida Deal Has Implications for Autoantibody Diseases

ByZachary Zubulake

August 31st 2026

PharmTech Weekly Roundup—August 28, 2026

BySusan Haigney

August 28th 2026

Pharma Fundamentals: Risks and Regulations for Hold Times in Biopharmaceuticals

ByRobert Dream,Susan Haigney

August 27th 2026

Semisolid Formulation Development: The CRO Approach - SP Formulations Whitepaper

Related Content

Regulatory Roundup—August 2026

From Detection to Prediction: Analytical Approaches for Nitrosamine Risk

Lilly's $2.875B Merida Deal Has Implications for Autoantibody Diseases

PharmTech Weekly Roundup—August 28, 2026

Pharma Fundamentals: Risks and Regulations for Hold Times in Biopharmaceuticals

Trending on Pharmaceutical Technology

Pharma Fundamentals: Risks and Regulations for Hold Times in Biopharmaceuticals

Rasonque's 60% Survival Benefit: What It Means for Oncology Pipelines

Pharma's Next AI Problem Is Authority

Lilly's $2.875B Merida Deal Has Implications for Autoantibody Diseases

What to Know from the FDA’s End of August Activity